A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors

NCT00499499 · clinicaltrials.gov ↗
PHASE1
Phase
SUSPENDED
Status
40
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Eisai Inc.